



Fully functional DEM1 test-chips MRSA from batch based backend processing

Deliverable 7.3

R2R Biofluidics Identifier	R2R Biofluidics_D07.3_Fully functional DEM1 test-chips MRSA from batch based backend processing_r0_FINAL
Submission date	February 28 th , 2019
Actual date of submission	May 07 th , 2019
Responsible partner	11 - GSB
Internal reviewer	1 - JR
Formal check	3 - BNN
Confidentiality	<u>public</u>

DOCUMENT HISTORY

Version	Date	Status of document / Reason of change (responsible person)
1	2019-03-01	Summary of previous activities by Max Sonnleitner (GSB)
2	2019-03-15	Confirmation from PO Matteo Bonazzi, that no new deliverable is necessary
3	2019-04-25	Termination of document by Martin Smolka (JR)
4	2019-05-07	Formal check by Ladenhauf (BNN)
5	2019-05-07	Final document submitted by Smolka (JR)

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement n° 646260.



Table of contents

1	OVERVIEW OF PREVIOUS CONFIGURATIONS OF DEM 1	3
2	OUTLOOK	3

1 Overview of previous configurations of Dem 1

The GENSPEED test chip is an in-vitro diagnostic chip for point of care applications (GENSPEED Biotech, Austria). In D7.01 we have shown, that integration of imprinted optical structures in general allows increasing chemiluminescence signals and thus increasing sensitivity of the system. In deliverable D07.2 we described the results regarding the implementation of a full R2R imprinting process of the chip including both integration of optical structures and the whole microfluidic architecture and also showed results when benchmark testing the test-chips versus standard GENSPEED MRSA test-chips. The full functionality of this chip configuration was proven and the performance was comparable to a previous batch of commercial chips from injection molding. In consequence, all goals which were foreseen for the present deliverable D07.3 have already been fulfilled and reported with D07.2.

In a mail communication from March 15, 2019 the Project Officer agreed that no new document needs to be written, as all tasks were already successfully reported earlier and because this earlier report was a public deliverable, too. For all details, please refer to Deliverable D07.3.

2 Outlook

The future activities of the project will focus on the configuration and testing of foil based Dem 1 chip with the novel R2R microarray spotter unit. This will enable a new generation of low cost diagnostic chips. These activities will be reported in D7.4 (Evaluation report for DEM1 with batch based backend processes).